海外の治験の状況「HPV」での検索結果
30件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- De-ESCALaTE HPV
- Human Papillomavirus oropharyngeal squamous cell carcinoma. MedDRA version: 19.0 Level: PT Classification code 10057444 Term: Oropharyngeal neoplasm System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Ireland, Netherlands, United Kingdom
- 2012-01-05
Authorised
- HPV Vaccine Trial
- HPV induced cancers such as Head and Neck Squamous Cell Carcinoma (HNSCC), Anogenital Cancer, Cervical Cancer, Penile Cancer MedDRA version: 20.0 Level: PT Classification code 10067821 Term: Head and neck cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10008229 Term: Cervical cancer System Organ Class: 100000020977 MedDRA version: 20.0 Level: PT Classification code 10061424 Term: Anal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10034299 Term: Penile cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Spain, United Kingdom
- 2016-03-17
Authorised
- A phase IIIb, open, multi-centre gynaecological extension study for the follow-up of a subset of HPV-015 study subjects - HPV-062 EXT:015
- GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of pre-malignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18.
- Netherlands, Portugal, United Kingdom
- 2010-06-04
Authorised
- Study of the molecular mechanisms underlying the cross-neutralizing capacity of AS04-adjuvanted HPV vaccine (Cervarix®) in comparison with the aluminiumhydroxyphosphate sulphate adjuvanted HPV vaccine (Gardasil®)
- vaccin against the human papillomavirus MedDRA version: 17.0 Level: LLT Classification code 10046859 Term: Vaccination System Organ Class: 100000004865 ;Therapeutic area: Body processes [G] - Immune system processes [G12]
- Belgium
- 2013-06-03
Authorised
- Multicentre trial evaluating the immunogenicity of HPV vaccination in girls on immunosuppressive therapy. - PRIMAVERA
- Infection by HPV 6, 11, 16, 18;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- France
- 2012-01-05
Authorised
- HPV vaccine for the treatment and prevention of recurrent laryngeal papillomatosis, which is a bening tumor in the upper airways caused by HPV
- Recurrant respiratory papillomatosis;Therapeutic area: Diseases [C] - Ear, nose and throat diseases [C09]
- Hungary
- 2013-11-04
Authorised
- A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines - RCT of immune response in UK adolescent girls to HPV vaccines
- This study will investigate vaccines that prevent premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. This study will investigate whether immunisation against infection with HPV 16 and 18 may impact on other oncogenic HPV types, through cross-protection. MedDRA version: 9.1 Level: LLT Classification code 10058580 Term: Human papilloma virus serology test
- United Kingdom
- 2009-04-16
Authorised
- Imiquimod therapy after surgical removal of anal HPV-lesions to reduce likelihood of recurrence
- anal HPV-lesions;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
- Austria
- 2018-01-11
Authorised
- Phase IIa trial of neoadjuvant AMG 319 in human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC).
- human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC) MedDRA version: 20.0 Level: PT Classification code 10060121 Term: Squamous cell carcinoma of head and neck System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- United Kingdom
- 2015-05-05